Lumos Receives FebriDx Order from PHASE Scientific
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The order is part of a distribution agreement and will be delivered progressively until the end of the year. This order follows a significant prepayment milestone received after a regulatory approval for FebriDx by the U.S. FDA. CEO Doug Ward expressed optimism about the order's timing as healthcare providers prepare for the flu season.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings CallLumos Diagnostics Holdings Ltd. on 6ix
Story so far
Earlier from Lumos Diagnostics
- FebriDx Commercial Traction Across Priority US Accounts
- FebriDx U.S. Rollout and Reimbursement Update - Amended
- FebriDx U.S. Rollout and Reimbursement Update
- FebriDx Paediatric Study Enrolment Milestone Achieved
- Response to ASX Aware Letter
Later from Lumos Diagnostics
- FY26 Appendix 4E
- FY26 Full Year Results Announcement
- FebriDx Commercial Traction Continues Across US Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics